Drugs / Cardenilimab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06574412 | Sep 2024 → Aug 2027 expected | clear cell renal carcinoma | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06165380 | Oct 2023 → Aug 2026 overdue | esophageal squamous cell carcinoma | Li Zhang | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cardenilimab | “Preoperative: Cardenilimab: 10 mg/kg qd intravenously, one cycle every 21 days, administered on the first day of each cycle, a total of 4 cycles.” NCT06574412 ↗ |
| Route | Intravenous | “Cardenilimab: 10 mg/kg qd intravenously” NCT06574412 ↗ |